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INTRODUCTION
Low-grade lymphoma and chronic lymphocytic leukemia
(CLL) are indolent lymphoproliferative disorders with
median survival times of 7 to 10 years [1-4]. Despite this
indolent course, patients with higher stages of the disease, as
well as those refractory to initial treatments have median sur-
vival times of less than 2 to 4 years [4,5]. There are many
available therapies for these disorders, but relapse almost
inevitably occurs [4]. Mantle cell lymphoma (MCL) is also
incurable with standard chemotherapies but has a more
aggressive course, with a median survival of 3 years [4,6]. 
High-dose therapy with autologous blood or bone mar-
row transplantation (BMT) has been performed successfully,
and the toxicity observed is comparable to that observed in
other diseases with this procedure. Several investigators
have reported on their results of durable remissions [7-14].
However, many of these studies with longer follow-up times
report a continuous relapse rate, suggesting that autologous
BMT is similar to other chemotherapy modalities in its fail-
ure to cure these diseases [11,12,15-17]. In addition,
myelodysplasia is emerging as an important problem, occur-
ring in up to 20% of patients in some series [18-20]. 
Allogeneic BMT offers several potential advantages over
autologous transplantation: it has graft-versus-lymphoma
(GVL) effect; it is a source of stem cells free of neoplastic
cells; and the marrow has not been exposed to chemotherapy
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ABSTRACT
Purpose: To report survival outcomes of allogeneic BMT in patients with low-grade lymphoma or mantle cell lym-
phoma (MCL).
Patients and Methods: Thirty-five patients with low-grade lymphoma (48%), chronic lymphocytic leukemia (26%),
or MCL (26%) underwent myeloablative allogeneic BMT from HLA-identical siblings at the Johns Hopkins Oncol-
ogy Center. Patients had a median age of 46 years, a median of 2 prior treatments, and 31% were in complete remis-
sion at the time of transplantation. The preparative regimen was cyclophosphamide/total body irradiation for most
patients. All grafts were T-cell depleted by counter flow centrifugal elutriation with CD34+ augmentation.
Results: The incidence of acute GVHD grade >2 was 6% and of grades 1 to 2 was 37%. The incidence of chronic
GVHD was 6%. The median follow-up time was 25 months. The rate of event-free survival (EFS) was 50% (95%
confidence interval [CI], 33%-66%). Only 1 patient relapsed. The transplantation-related mortality (TRM) was 46%
for all patients. The TRM was 86% for patients with resistant disease and 14% for patients with sensitive disease
and <2 prior treatments; rates of EFS were 0% (95% CI, 0%-0%) and 79% (95% CI, 47%-93%), respectively.
Conclusion: These data show that, with T-cell depletion, the TRM and relapse rates are modest for patients with
sensitive disease and <2 prior treatment courses. Thus, if there is a role for allogeneic BMT in the management of
patients with these tumors, it is early in the course of the disease.
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mutagens. Although the use of allogeneic transplantation in
cases of low-grade lymphomas and CLL has been reported
from many centers [15,17,21-37], the median older age of
the patient population, the high rates of graft-versus-host
disease (GVHD), and associated high transplantation-
related mortality (TRM) have limited the use of this
approach. We report the results of 35 consecutive patients
with low-grade lymphoma, CLL, or MCL who underwent
T cell–depleted allogeneic BMT by elutriation at the Johns
Hopkins Oncology Center.
PATIENTS AND METHODS
Patients
Thirty-ﬁve consecutive patients with diagnoses of low-
grade lymphoma (n = 17), CLL/small lymphocytic lym-
phoma (SLL) (n = 9), or MCL (n = 9), according to the
Working Formulation or REAL (Revised European Ameri-
can Lymphoma) classifications [38,39], underwent allo-
geneic BMT from HLA-identical siblings between January
1992 and September 1, 1999 at the Johns Hopkins Oncol-
ogy Center. Patients with follicular large cell lymphoma or
transformation to a high-grade lymphoma prior to trans-
plantation were excluded. All pathology specimens were
reviewed by the Pathology Department at Johns Hopkins
University. All patients met the following protocol eligibility
criteria: (1) age, ≥60 years; (2) Karnofsky Performance
Score, ≥70%; (3) left ventricular ejection fraction, ≥45%; (4)
both forced expiratory volume in 1 second and diffusing
capacity for carbon monoxide, ≥50% (75% in patients who
received thoracic irradiation); (5) total bilirubin, ≤2.0 mg/dL;
(6) creatinine, <2.0 mg/dL; and (7) human immunodefi-
ciency virus, negative. All patients provided written informed
consent and were treated with protocols approved by the
institutional review board.
Disease response was evaluated according to standard
criteria for non-Hodgkin’s lymphoma [40] and CLL [41].
Sensitive disease was deﬁned as achieving at least a partial
remission with the last chemotherapeutic intervention prior
to allogeneic BMT.
Conditioning Regimens
Thirty-one patients received cyclophosphamide, 50 mg/kg
per day, intravenously (IV) for 4 days followed by total body
irradiation (TBI), 1200 cGy, given as 300 cGy/d × 4 days at a
rate of 9 to 10 cGy/min, with the lungs shielded beginning on
the third day of treatment [42]. Four patients who had
received radiation prior to transplantation received busulfan
1 mg/kg per dose orally (PO) every 6 hours for 16 doses over
4 days, with dosing adjusted on the second and subsequent
days based on pharmacokinetic studies and the area under the
curve of busulfan. The 4 patients then received cyclophos-
phamide, 50 mg/kg per day, IV for 4 days [43].
Donors
The donor marrow sources were HLA-matched siblings
in all cases. All grafts were manipulated by T-cell depletion
using counter ﬂow centrifugal elutriation along with CD34+
augmentation via positive selection [44,45]. This procedure
resulted in a reduction of T cells in the graft to an average
of 5.5 × 105 CD3+ T cells/kg.
Supportive Care
All patients were treated in HEPA ﬁltered rooms with
reverse isolation and received GVHD prophylaxis consisting
of cyclosporin A, 5 mg/kg per day IV, with rapid conversion
to oral dosing and a target maintenance dose of 7.5 mg/kg
per day PO for a period of 6 months. Each patient received
infection prophylaxis consisting of ﬂuconazole, vancomycin,
and an oral fluoroquinolone. Patients positive for herpes
simplex virus received acyclovir or a derivative as prophy-
laxis. Pneumocystis prophylaxis was trimethoprim/sul-
famethoxazole or aerosolized pentamidine for a minimum of
6 months following transplantation and longer if immuno-
suppressive agents were continued for management of
GVHD. Blood products were irradiated.
Posttransplantation Evaluation and Response Criteria
All patients were followed daily until full engraftment
occurred and all acute issues were resolved. Patients then
underwent scheduled evaluations, including complete tumor
measurements, at approximately day 100, 6 months, and
once a year thereafter. GVHD was graded according to
standard criteria [46,47]. 
Statistical Methods
The primary treatment outcomes evaluated were event-
free survival (EFS) and TRM. EFS was deﬁned as survival
without any evidence of lymphoma posttransplantation. For
EFS evaluation, patients were censored at the time of
relapse or death from any cause; patients alive in continuous
remission were censored at the last follow-up evaluation.
TRM was defined as any death occurring within the first
100 days after transplantation or any death determined to
have occurred as a direct result of the transplantation proce-
dure. Other outcomes evaluated included rates of both acute
GVHD and chronic GVHD.
Event-time distributions were estimated using the
method of Kaplan and Meier [48] and compared using the
log-rank statistic [49] or the proportional hazards regression
model [50]. Factors tested for prognostic value included age,
diagnosis, sex, patient/donor-sex mismatch, preparative regi-
men, resistance of disease, cytomegalovirus (CMV) positivity,
and fludarabine use. In univariate analysis, the number of
previous treatments was entered as a continuous effect and
the relative hazard reﬂects the risk of death per unit change
in the value of the factor. Other variables were entered as
binary effects and the estimated hazard ratios (HRs) for these
factors reﬂect either their presence or absence. Diagnosis is a
categorical variable for more than 2 groups, and the HRs are
expressed relative to the CLL group having been arbitrarily
chosen as the reference category.
All P values reported are 2-sided. Computations were
performed using the Statistical Analysis System [51] or
EGRET software [52].
RESULTS
Patient Characteristics
Patient characteristics for the entire cohort are listed in
Table 1. The median age of the cohort was 46 years. The
majority of patients had advanced-stage disease and only 31%
were in complete remission at the time of transplantation. Of
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the patients, 80% were considered sensitive to the treatment
regimen given immediately prior to transplantation. The
median number of treatments received prior to transplanta-
tion was 2 (range, 1-6).
Outcomes
The median time to an absolute neutrophil count of
>500 × 109/L for 2 consecutive days was 18 days; the median
time to a transfusion-independent platelet count of >20 ×
109/L was 16 days.
Sixteen (46%) patients died of transplantation-related
causes (Table 2). Transplantation-related deaths were
divided into early and late. An early death was deﬁned as any
death occurring within 100 days after transplantation. A late
death was defined as any death occurring more than
100 days after transplantation. Conditioning-regimen toxic-
ity, late infections, multiorgan failure, and pulmonary toxic-
ity were the most common causes of TRM.
The rate of acute GVHD grade >2 was 6%. The rate of
acute GVHD grade 1 and grade 2 was 37%. Chronic
GVHD was seen in only 2 patients (6%). Only 1 patient died
of GVHD.
At a median follow-up of 25 months, the EFS rate was
50% (95% CI, 33%-66%) (Figure 1). An increasing number
of previous treatments, resistant disease, and diagnosis of
MCL, follicular mixed lymphoma (FML), or follicular
small-cleaved lymphoma (FSC) were significant factors
associated with lower EFS rates in univariate analyses
(Table 3). Patients with resistant disease had a hazard ratio
of 4.44 (95% CI, 1.49-13.2), P = .007, compared to those
not having resistant disease. Compared to patients with
CLL, patients with MCL, FML, and FSC had signiﬁcantly
Table 1. Patient Characteristics*
Characteristic No. of Patients Percentage of Total Median (Range)
Total patients 35 100%
Male patients 23 66%
Age at transplantation, y 46 (26-61)
Patient age
≥40 years 28 80%
<40 years 7 20%
Recipient CMV-positive serology 19 54%
Histology
Small lymphocytic/CLL 9 26%
Follicular small-cleaved 6 17%
Follicular mixed 10 27%
Mantle cell 9 26%
MALT 1 3%
Disease stage at diagnosis (non-CLL)
I 1 3%
II 3 10%
III 8 27%
IV 16 53%
Disease stage at diagnosis for CLL using modified Rai staging
Low 2 29%
Intermediate 4 57%
High 1 14%
Patients in CR at transplantation 11 31%
Response to chemotherapy
Sensitive 28 80%
Resistant 7 20%
Prior treatment regimens, n 2 (1-6)
Time interval from diagnosis to BMT, mo 21 (5-144)
Year of transplantation
1994-1996 9 26%
1997-1999 26 74%
Donor-recipient sex match
M-M 6 17%
M-F 4 11%
F-M 16 46%
F-F 8 23%
Unknown 1 3%
Conditioning regimen
Cy/TBI 31 89%
Bu/Cy 4 11%
Fludarabine treatment prior to BMT 12 34%
*MALT indicates mucosa-associated lymphoid tumors; CR, complete remission; Cy, cyclophosphamide; Bu, busulfan.
J.G. Berdeja et al.
564
lower EFS rates: HR = 13.1 (95% CI, 1.59-108.8), P = .02;
HR = 9.84 (95% CI, 1.16-83.2), P = .04; and HR = 7.89
(95% CI, 0.92-68.0), P = .06, respectively. An increasing
number of previous treatments was also associated with a
lower EFS rate (HR = 1.49 [95% CI, 1.07-2.07]), P = .02.
Patients given fludarabine had a slightly improved EFS
rates (HR = 0.56 [95% CI, 0.20-1.56]), but this ﬁnding was
not significant (P = .27). Age, CMV positivity, sex, and
patient/donor-sex mismatch were not prognostic for EFS.
Adjusting for previous treatments and resistant disease,
patients with MCL had an HR of 14 (95% CI, 1.2-120.5)
compared to the CLL patients (P = .01). FML and FSC
likewise had an adverse effect on EFS (HR = 5.3 [95% CI,
0.7-42.2]), but this result was not signiﬁcant (P = .11). Previ-
ous treatments were grouped to compare patients with only
1 previous treatment to those having >1 previous treatment.
Adjusting for diagnosis and resistant disease, those with
>1 previous treatment had 3.8 times the risk of lower EFS
rates (95% CI, 1.00-14.18) than the group with only 1 prior
treatment (P = .05). Resistant disease also increased the risk
of a lower rate of EFS; HR = 3.0 (95% CI, 0.91-9.50), P = .07,
after adjustment for diagnosis and previous treatments.
After adjusting for histologic diagnosis and using the
2 most signiﬁcant parameters predictive of a worse outcome,
resistant disease and >1 treatment prior to transplantation,
distinct differences in the TRM and overall survival
emerged. The TRM for patients with resistant disease and
≥2 prior treatments was 86%. The TRM for patients with
sensitive disease and ≥2 prior treatments was 57%. On the
other hand, the TRM for patients with sensitive disease and
<2 prior treatments was 14% (Table 4). Similarly, the
Kaplan-Meier EFS curves for these 3 groups are shown in
Figure 2. At a median follow-up time of 25 months, the
EFS rate was 79% (95% CI, 47%-93%) for the sensitive
and <2-prior-treatments group, 32% (95% CI, 10%-57%)
for the sensitive and ≥2-prior-treatments group, and 0%
(95% CI, 0%-0%) for the resistant and ≥2-prior-treatments
group. The patient characteristics of the 3 groups are shown
in Table 5. Finally, the EFS was 23.3% (95% CI, 7.5%-
44%) and the TRM was 62% for the group of patients with
≥2 prior treatments, regardless of disease sensitivity.
DISCUSSION
The TRM of 46% and the EFS of 50% reported in the
present series is in line with previously published reports
Table 2. Causes of Death*
No. of Patients Percentage of Total
Transplantation related 16 46%
Early death† 10
Pulmonary 3
Multiorgan failure 3
VOD 1
CNS hemorrhage 1
Lymphoma 1
Infection 1
Late death† 6
Late infections 3
HUS 1
Multiorgan failure 1
GVHD 1
Progressive disease 1 3%
Pulmonary 1 3%
Subsequent malignancy‡ 1 3%
*VOD indicates veno-occlusive disease; CNS, central nervous sys-
tem; HUS, hemolytic uremic syndrome.
†Early death is deﬁned as death within the ﬁrst 100 days posttrans-
plantation; late death, after 100 days posttransplantation.
‡This patient died of an unrelated pancreatic carcinoma 5 years
after transplantation, without evidence of recurrence of original lym-
phoproliferative disease.
Figure 1. Event-free survival. The Kaplan-Meier EFS rate at a
median follow-up of 25 months for the entire cohort of 35 patients was
50% (95% CI, 33%-66%). 
Table 3. Factors Tested for Effect on Survival of Patients With Low-Grade
Lymphoma and CLL: Univariate and Multivariate Analyses
Hazard Ratio 95% CI P
Univariate analysis
Fludarabine use 0.56 0.20-1.56 .27
Recipient CMV positivity 0.79 0.32-1.95 .61
Age 1.07 0.99-1.12 .07
Recipient/donor sex mismatch 1.20 0.48-3.01 .69
Male sex 1.91 0.63-5.85 .26
Increasing no. of prior treatments 1.49 1.07-2.07 .02
Resistant disease 4.44 1.49-13.2 .007
Diagnosis
FSC 7.89 0.92-68.0 .06
FML 9.84 1.16-83.2 .04
MCL 13.13 1.59-108.8 .02
Multivariate analysis
Diagnosis 
MCL 14.29 1.19-120.5 .01
FML/FSC 5.31 0.67-42.18 .11
>1 Previous treatment 3.76 1.00-14.18 .05
Resistant disease 2.95 0.91-9.50 .07
AlloBMT in Low-Grade Lymphoma
565B B & M T
from various investigators on allogeneic BMT in low-grade
lymphomas [21-37]. The largest of these studies was the
International Bone Marrow Transplant Registry series,
which reported an EFS of 49%, TRM of 40%, acute
GVHD of 27%, and chronic GVHD of 66% [31]. Further-
more, small series suggest that MCL patients appear to have
a poor outcome following allogeneic BMT [53-54]. Like-
wise, in the series reported here, carrying the diagnosis of
MCL was the strongest negative predictor for outcome.
Interestingly, however, the data presented here suggest
that it may be possible to stratify prospective allogeneic trans-
plant recipients into distinct risk groups regardless of their
individual histologies. Figure 2 clearly identifies 3 distinct
groups of patients with divergent rates of both TRM and
overall survival depending on the presence of 0, 1, or 2 risk
factors. Risk factors predicting an adverse outcome identiﬁed
by multivariate analysis were resistant disease and ≥1 treat-
ment course prior to transplantation. The group with both
risk factors had a high TRM of 86% and none of these
patients was alive at 6 months. The group expressing 1 factor
(>1 prior treatment; there were no patients with resistant dis-
ease and ≤1 prior treatment) had an intermediate TRM rate
of 57% and an EFS of 32% at a median follow-up of 25
months. The group expressing neither of these risk factors
had a TRM of only 14% and EFS of 79% at a median follow-
up of 25 months. Similarly, the high TRM of 62% and EFS
rate of 23% in the group with ≥2 prior treatments further
illustrate the prognostic implication of prior treatments alone
for outcome. The characteristics of the patients in each subset
are depicted in Table 5. The patients in the 2-risk-factor
group were slightly older than the patients in the other 2
groups, but there was no significant difference in age
between the 0- and 1-risk-factor groups, although they still
showed signiﬁcantly different outcomes. The subgroup num-
bers were too small to determine statistical signiﬁcance, but it
should be noted that age alone was not a signiﬁcant risk factor
predicting poor outcome in univariate analysis of the entire
group. The 0-risk-factor group had a slightly higher number
of CLL patients, but had an even greater number of MCL
patients, which likely balances the prognostic implications of
the different histologies in the various groups.
The rates of acute and chronic GVHD seen in this cohort
compare favorably to that reported in the literature of
mixed and/or non–T-cell–depleted populations
[23,27,28,31,33,35]. The difference was especially striking in
the extremely low rates of grades 3 and 4 acute GVHD and
chronic GVHD observed. Another important observation is
that the rates of acute GVHD in the different subsets stratiﬁed
by risk factors were quite different and may partly account for
the different rates of TRM observed. The group without any
adverse risk factors had an incidence of 7% acute GVHD and
0% chronic GVHD. The group with 1 adverse risk factor had
incidences of 43% acute GVHD and 14% chronic GVHD.
Finally, the group with 2 risk factors had incidences of 43%
acute GVHD and 0% chronic GVHD. The low rate of
chronic GVHD observed in the latter group is not unexpected
given the lack of survivors beyond the 6-month interval. This
data points to the relative importance of controlling GVHD
and subsequent TRM. The low rates observed are likely due
to the use of T-cell depletion by elutriation as has been
reported by this group for other disease subsets [44,45].
A concern with any T-cell–depletion protocol is the
potential adverse impact on the GVL effect. T-cell deple-
tion by elutriation as used in this cohort of patients causes
significant but incomplete T-cell depletion. Furthermore,
relapse rates with T cell–depleted BMT in lymphoma and
other hematologic disorders similar to those observed in
nonmanipulated grafts have been reported [36,44]. The
Table 4. 
Transplantation-Related Mortality (TRM) by Disease Sensitivity
Total TRM 46%
TRM in patients with resistant disease and ≥2 prior treatments 86%
TRM in patients with sensitive disease and ≥2 prior treatments 57%
TRM in patients with sensitive disease and <2 prior treatments 14%
Figure 2. Event-free survival.The Kaplan-Meier EFS rates for 3 dis-
tinct subgroups, based on the presence of no risk factors, 1 risk factor,
or 2 risk factors (both resistant disease and >1 prior treatment). At a
median follow-up of 25 months, the EFS rates were 79%, 32%, and
0%, respectively. Rx indicates treatments.
Table 5. 
Patient Characteristics for Select Subgroups
All Sensitive, Sensitive, Resistant,
Patients <2 Rx ≥2 Rx ≥2 Rx
No. of patients 35 14 14 7
Male patients 66% 43% 79% 86%
Median age, y 46 43 46 53
Histology
SLL/CLL 9 (26%) 5 (36%) 3 (21%) 1 (14%)
Follicular 16 (46%) 3 (21%) 9 (64%) 4 (57%)
MCL 9 (26%) 5 (36%) 2 (14%) 2 (28%)
MALT 1 (3%) 1 (7%) 0 (0%) 0 (0%)
Median interval to BMT, mo 21 10 31 27
Acute GVHD (grade ≥2) 31% 7% 43% 43%
Chronic GVHD 6% 0% 14% 0%
No. of patients relapsed 1 0 1 0
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pattern of minimal relapse in this cohort of patients at
25 months post-BMT suggests a potential GVL effect,
although longer follow-up will be paramount given the
potential for late relapses in these patients.
The data reported in this retrospective study challenges
the common practice of reserving allogeneic BMT as a
modality of last resort. Instead, the low rates of GVHD and
subsequent low TRM seen in patients with sensitive disease
and <2 prior treatments suggest that if there is a role for allo-
geneic BMT in the treatment of patients with low-grade or
mantle cell lymphomas, it is early in the course when
patients have sensitive disease and have not been heavily
treated. Long-term follow-up will determine whether this
decrease in transplantation-related mortality will ultimately
translate into an increase in survival for this patient popula-
tion. The high TRM in the patients with >1 prior treatments
and/or resistant disease should prompt further investigation
in this patient population with alternate transplantation tech-
niques, such as the use of nonmyeloablative allogeneic or
purged autologous BMT or enrollment in clinical trials.
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